Research Article
Endocan, a Risk Factor for Developing Acute Respiratory Distress Syndrome among Severe Pneumonia Patients
Table 2
Laboratory tests of SP patients with or without ARDS development.
| | Laboratory tests | SP with ARDS development | value | | Yes (n = 37) | No (n = 108) |
| | Hemoglobin (g/L) | 103.1 ± 25.1 | 106.5 ± 30.1 | 0.54 | | Hematocrit (%) | 33.4 ± 6.4 | 32.7 ± 5.8 | 0.54 | | Platelet (109/L) | 171.7 ± 102.2 | 180.4 ± 110.8 | 0.68 | | Albumin (g/L) | 29.1 ± 6.3 | 27.4 ± 7.5 | 0.22 | | ALT (IU/L) | 65.5 ± 88.1 | 45.4 ± 66.8 | 0.15 | | AST (IU/L) | 58.4 ± 102.3 | 38.4 ± 77.4 | 0.22 | | BUN (mmol/L) | 11.5 ± 6.2 | 9.3 ± 5.5 | 0.044 | | Creatinine (µmol/L) | 101.2 ± 48.5 | 78.4 ± 50.1 | 0.017 | | Lactate (mmol/L) | 2.2 ± 1.5 | 1.5 ± 1.1 | 0.003 | | Endocan (ng/mL) | 13.4 ± 7.2 | 8.5 ± 4.1 | <0.001 | | T cell immunity (%) | | | | | CD3+ | 59.4 ± 14.2 | 57.1 ± 16.3 | 0.45 | | CD4+ | 27.1 ± 12.4 | 27.9 ± 14.5 | 0.76 | | CD8+ | 28.9 ± 11.7 | 25.4 ± 12.2 | 0.13 | | Inflammatory biomarkers | | | | | CRP (ng/L) | 129.5 ± 152.4 | 85.7 ± 116.7 | 0.034 | | Interleukin-6 (ng/mL) | 1035.4 ± 783.2 | 886.5 ± 568.7 | 0.22 | | Procalcitonin (ng/mL) | 3.5 ± 5.3 | 4.7 ± 7.1 | 0.35 | | Arterial blood gas | | | | | pH | 7.40 ± 0.09 | 7.38 ± 0.08 | 0.21 | | PaCO2 (mmHg) | 40.1 ± 13.1 | 42.2 ± 12.8 | 0.396 | | HCO3− (mmol/L) | 23.6 ± 5.1 | 24.1 ± 5.3 | 0.62 | | PaO2/FiO2 (mmHg) | 129.3 ± 35.8 | 152.1 ± 45.1 | 0.006 |
|
|
SP, severe pneumonia; ARDS, acute respiratory distress syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; PaCO 2, partial pressure of arterial carbon dioxide; HCO 3−, bicarbonate ion; PaO 2/FiO 2, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen. values were calculated by Student’s t-test or Mann–Whitney U-test. . |
